Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
Status:
Completed
Trial end date:
2019-06-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is the proof of mechanism and support of dose finding,
together with the safety evaluation in patients with clinical evidence of NASH.
To gain further insight into clinical effects of AOC3 inhibition on NASH further exploratory
analyses of biomarkers related to NASH and liver fibrosis will be performed. This will
include the effect of BI 1467335 on reduction of secondary biomarker endpoints (ALT, AST, AP,
γ-GT and CK18 fragments). Safety will be assessed throughout the study to provide key
information regarding the use of BI 1467335 in patients with NASH.